DGAP-News

SuppreMol GmbH: Baxter's Bioscience Business acquires biopharmaceutical Company SuppreMol

DGAP-News: SuppreMol GmbH / Key word(s): Mergers & Acquisitions
SuppreMol GmbH: Baxter's Bioscience Business acquires
biopharmaceutical Company SuppreMol

04.03.2015 / 15:05

---------------------------------------------------------------------

Press Release

Baxter's Bioscience Business acquires biopharmaceutical Company SuppreMol

Acquisition includes SuppreMol's early-stage pipeline of protein
therapeutics for autoimmune and allergic diseases

DEERFIELD, Ill., USA, and Munich, Germany, March 4, 2015 - Baxter
International Inc. (NYSE:BAX) and SuppreMol GmbH today announced that
Baxter has acquired SuppreMol for EUR 200 million (approximately USD 225
million) before working capital and other adjustments. SuppreMol is a
privately held biopharmaceutical company based in Martinsried, Germany
developing treatment options for autoimmune and allergic diseases.

The acquisition includes SuppreMol's early-stage development portfolio of
novel biologic immunoregulatory therapeutics for the treatment of
autoimmune diseases, focusing on the modulation of Fc receptor signaling
pathways, an immune target that could have broad applications in autoimmune
disorders. In addition to the portfolio, Baxter also acquires and will
continue to operate SuppreMol's operations in Munich.

SuppreMol's pipeline includes lead candidate SM101, an investigational
immunoregulatory treatment that has completed Phase 2a studies in
idiopathic thrombocytopenic purpura (ITP, a disorder causing low platelet
levels) and systemic lupus erythematosus (SLE, a disorder in which the
immune system attacks healthy tissue). SM101's Phase 2a data, presented
during the American College of Rheumatology's 2014 annual meeting, showed a
dose response in multiple endpoints among patients with SLE treated with
either one of two different doses of SM101 for six months. The pipeline
also includes technologies with potential therapeutic applications in other
autoimmune diseases as well as IgE-mediated allergic diseases.

"SuppreMol's portfolio of novel investigational treatments complements and
builds upon our leading and differentiated immunology portfolio, offering
the opportunity to expand into new areas with significant market potential
and unmet medical needs in autoimmune diseases," said Ludwig Hantson,
Ph.D., president of Baxter BioScience.

"Matching therapeutic innovation with market needs is challenging for